The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease

被引：2

作者：

Lincoff, A. Michael ^{[1
]}

Ryan, Donna H. ^{[2
]}

机构：

[1] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Cardiovasc Med, Cleveland, OH USA

[2] Pennington Biomed Res Ctr, Baton Rouge, LA USA

来源：

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 02期

关键词：

D O I：

10.1093/ehjcvp/pvad097

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：93 / 94

页数：2

共 50 条

[31] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Rubino, Domenica M.
Greenway, Frank L.
Khalid, Usman
O'Neil, Patrick M.
Rosenstock, Julio
Sorrig, Rasmus
Wadden, Thomas A.
Wizert, Alicja
Garvey, W. Timothy
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (02): : 138 - 150
[32] Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with myocardial infarction - Reply
Nilsson, PM
Berglund, G
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) : 182 - 182
[33] A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart Disease Among Patients with Diabetes and/or Obesity
Osude, Nkiru
Pagidipati, Neha J.
MEDICAL CLINICS OF NORTH AMERICA, 2024, 108 (03) : 469 - 487
[34] Targeting Inflammation with Salicylate (Salsalate) Improves Glycemia over 30 Months in a Randomized Trial of Overweight Patients without Diabetes and with Stable Cardiovascular Disease
Salastekar, Ninad
Desai, Tanvi
Schaefer, Ernst
Hauser, Thomas
Clouse, Melvin
Joseph, Stacey
Fowler, Kristen
Shoelson, Steven E.
Goldfine, Allison B.
DIABETES, 2016, 65 : A518 - A518
[35] Risk of Secondary Cardiovascular Disease and All-Cause Mortality among Patients with and without Diabetes
Nichols, Gregory A.
Pedula, Kathryn L.
Wang, Fang
Bell, Timothy J.
DIABETES, 2009, 58 : A27 - A27
[36] CANAGLIFLOZIN VERSUS SEMAGLUTIDE FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - VALUE PER MONEY ANALYSIS
Arbel, Ronen
Hammerman, Ariel
Aboalhasan, Enis
Azuri, Joseph
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1610 - 1610
[37] Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus is improved using the Alphabet Strategy
Lee, J. D.
Venkataraman, A.
Haider, Y.
Patel, V.
EUROPEAN HEART JOURNAL, 2006, 27 : 533 - 533
[38] Comparison of treatment outcomes in patients with and without diabetes mellitus attending a multidisciplinary cardiovascular prevention programme (the EUROACTION trial)
Ofori, S.
Kotseva, K.
EUROPEAN HEART JOURNAL, 2014, 35 : 741 - 741
[39] Therapeutic education of patients with overweight and obesity regarding the knowledge about ischemic heart disease and secondary prevention of myocardial infarction.
Ratajczak, J.
Michalski, P.
Kosobucka, A.
Pietrzykowski, L.
Siedlaczek, M.
Kubica, A.
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2020, 19 (1_SUPPL) : S14 - S14
[40] Semaglutide Provides More Value for Money Than Dulaglutide or Liraglutide for Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease
Azuri, Joseph
Aboalhasan, Enis
Hammerman, Ariel
Arbel, Ronen
CIRCULATION, 2020, 142

← 1 2 3 4 5 →